P-1688. Differences in Guideline-Concordant Antibiotic Prescribing Based on Age, Sex, Race, and Ethnicity for the Management of Inpatients with Community-Acquired Bacterial Pneumonia (CABP) due to Pseudomonas aeruginosa: a Retrospective Cohort Analysis of the All of Us Database
Abstract
Abstract Background This is one of the first studies to evaluate health disparities in antibiotic prescribing for inpatients with community-acquired bacterial pneumonia (CABP) from Pseudomonas aeruginosa.Table 1. Patient Baseline Characteristics, by Guideline-Concordant and Discordant Antibiotics * Bold italics indicates statistically significant findings. + Some groups contain non-exact participant counts to prevent displaying any participant count that is less than 20 and to comply with the All of Us data and statistic dissemination policy. Methods Inpatients with CABP due to P. aeruginosa (SNOMED: 41381004) were identified in the All of Us database (2016-2022). Patients with treatment settings other than inpatient, other pathogens, and other pneumonia types were excluded. Patients were grouped by age, sex, race, and ethnicity. The proportion of patients prescribed guideline-concordant and guideline-discordant anti-pseudomonal antibiotics (GCAB and GDAB) were compared with chi-square. GCAB (2019 IDSA/ATS CABP guidelines), were: aztreonam, cefepime, ceftazidime, imipenem, meropenem, and piperacillin-tazobactam. Significant associations between patient characteristics and prescribing (p < 0.05) were assessed using multivariate logistic regression, with subgroup as the independent variable, anti-pseudomonal prescribing as the dependent variable, and divergent baseline characteristics as confounders. Odds ratios (OR) and 95% confidence intervals (95% CI) for receipt of GCAB…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 119 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.